Entries by Michael Kuhrt

Magyosz chair

In early June, the Hungarian National Association of Drugmakers (Magyosz) elected István Hodász as its general chairman. Hodász is CEO and managing director of the Egis Pharmaceuticals Plc, a unit of France’s Servier.

Going home

When Sanofi sells its animal health division Merial, CEO Carsten Hellmann will join Danish allergy specialist ALK Albello as the next President and CEO. He will also give up his seat on the Executive Committee and his position of Executive Vice President at Sanofi.

Go West

British research service provider Envigo has appointed Scott Schulz to the post of Director, North American Operations. Schulz joins Envigo from Taconic Biosciences, where he was VP of Operations.

Founder on board

Frode Marc Bohan has been reelected as Chairman of the Board of Directors for Norwegian Vitamin K2 expert NattoPharma ASA. He will continue to chair the board for the next two years.

Scientific insight

Swedish preeclampsia drug developer A1M Pharma has named Hungarian kidney specialist József Balla as the newest member of its scientific advisory board.

Marketing man

Hansa Medical, a Swedish biopharmaceutical company focusing on novel immunomodulatory enzymes, has appointed Henk Doude van Troostwijk as Vice President, Commercial Operations.

The doctor is in

Belgian CRO and service provider Genea has appointed a new Chief Medical Officer. Jörn Balzer will be responsible for the clinical, safety and risk management in Genae’s research services.

Precision breeding smart rules for new techniques!

Plant breeding innovation is an impressive story to tell. A hundred and fifty years ago, Gregor Mendel discovered the basic principles of inheritance of traits. His laws were widely ignored and only in the 1920s, finally recognised as the fundament of population genetics. So it has only been a good 100 years that we have properly understood how to improve crops no longer randomly but in a targeted manner.

Going round in circles

I am too depressed to write about the UK playing silly buggers with the EU and the negative impact on science, so let’s look at something positive for Europe instead – the development of circular economy opportunities for biotechnology.